Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Rating) had its price target cut by research analysts at Berenberg Bank from €76.70 ($78.27) to €57.95 ($59.13) in a research report issued to clients and investors on Wednesday, The Fly reports.
Several other brokerages have also recently issued reports on FMS. Truist Financial reduced their target price on shares of Fresenius Medical Care AG & Co. KGaA from $34.00 to $27.00 and set a "hold" rating for the company in a report on Wednesday, June 22nd. StockNews.com cut shares of Fresenius Medical Care AG & Co. KGaA from a "strong-buy" rating to a "buy" rating in a report on Friday, July 15th. Jefferies Financial Group raised shares of Fresenius Medical Care AG & Co. KGaA from an "underperform" rating to a "buy" rating and raised their target price for the stock from $30.30 to $33.70 in a report on Monday, June 27th. UBS Group lowered shares of Fresenius Medical Care AG & Co. KGaA from a "buy" rating to a "neutral" rating in a research report on Friday, July 29th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Fresenius Medical Care AG & Co. KGaA from €51.00 ($52.04) to €23.00 ($23.47) in a research report on Monday, August 1st. One analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $45.83.
Get Fresenius Medical Care AG & Co. KGaA alerts:Fresenius Medical Care AG & Co. KGaA Trading Up 0.5 %
NYSE FMS opened at $18.85 on Wednesday. The company has a fifty day simple moving average of $23.68 and a two-hundred day simple moving average of $29.31. The stock has a market cap of $11.05 billion, a P/E ratio of 12.02, a P/E/G ratio of 0.92 and a beta of 1.02. Fresenius Medical Care AG & Co. KGaA has a 12-month low of $18.16 and a 12-month high of $40.85. The company has a current ratio of 1.18, a quick ratio of 0.85 and a debt-to-equity ratio of 0.47.
Hedge Funds Weigh In On Fresenius Medical Care AG & Co. KGaA
A number of institutional investors and hedge funds have recently bought and sold shares of FMS. Pzena Investment Management LLC boosted its position in Fresenius Medical Care AG & Co. KGaA by 47.6% during the fourth quarter. Pzena Investment Management LLC now owns 9,459,446 shares of the company's stock worth $307,054,000 after acquiring an additional 3,051,672 shares during the last quarter. First Trust Advisors LP raised its stake in Fresenius Medical Care AG & Co. KGaA by 15.1% during the fourth quarter. First Trust Advisors LP now owns 1,925,326 shares of the company's stock worth $62,496,000 after purchasing an additional 252,768 shares during the period. Bank of America Corp DE raised its stake in Fresenius Medical Care AG & Co. KGaA by 27.9% during the first quarter. Bank of America Corp DE now owns 1,083,689 shares of the company's stock worth $36,499,000 after purchasing an additional 236,459 shares during the period. Cambiar Investors LLC raised its stake in Fresenius Medical Care AG & Co. KGaA by 18.3% during the first quarter. Cambiar Investors LLC now owns 1,363,874 shares of the company's stock worth $45,935,000 after purchasing an additional 210,819 shares during the period. Finally, Invesco Ltd. raised its stake in Fresenius Medical Care AG & Co. KGaA by 54.0% during the fourth quarter. Invesco Ltd. now owns 376,173 shares of the company's stock worth $12,211,000 after purchasing an additional 131,870 shares during the period. 4.73% of the stock is currently owned by institutional investors and hedge funds.Fresenius Medical Care AG & Co. KGaA Company Profile
(Get Rating)
Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Further Reading
- Get a free copy of the StockNews.com research report on Fresenius Medical Care AG & Co. KGaA (FMS)
- Look at Honeywell for a Steady and Diversified Stock
- Why Invest in High-Yield Dividend Stocks?
- Find and Profitably Trade Stocks at 52-Week Lows
- Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
- Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.